Table: Sumitomo Pharma -2023/24 group results (IFRS)

Sumitomo Pharma

14/05/2024 05:00

May 14 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                  Year ended       Year ended        Year to         NEXT  
               Mar 31, 2024     Mar 31, 2023    Mar 31, 2025       YEAR    
                  LATEST          YEAR-AGO         COMPANY       COMPANY   
                 RESULTS           RESULT         FORECAST     H1 FORECAST 
  Sales           314.56           555.54          338.00                  
               (-43.4 pct)       (-0.8 pct)      (+7.5 pct)                
  Operating    loss 354.86       loss 76.98         0 mln                  
  Pretax
  Net          loss 314.97       loss 74.51      loss 16.00                
  EPS Basic  loss 792.79 yen  loss 187.55 yen  loss 40.27 yen              
  Ann Div          NIL           21.00 yen           NIL                   
  -Q2 Div          NIL           14.00 yen           NIL                   
  -Q4 Div          NIL            7.00 yen           NIL                   
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T